✦ LIBER ✦

Pharmacokinetics and safety of tobramycin administered by the PARI eFlow® rapid nebulizer in cystic fibrosis

✍ Scribed by Dominique Hubert; Sylvie Leroy; Raphaële Nove-Josserand; Marlène Murris-Espin; Laurent Mely; Stéphane Dominique; Bertrand Delaisi; Pearl Kho; John M Kovarik

Book ID: 119288704
Publisher: Elsevier Science
Year: 2009
Tongue: English
Weight: 188 KB
Volume: 8
Category: Article
ISSN: 1569-1993
DOI: 10.1016/j.jcf.2009.07.001

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

50 Pharmacokinetic comparison of inhaled

50 Pharmacokinetic comparison of inhaled tobramycin (TOBI®) via PARI eFlow® rapid or PARI LC Plus™ nebulizers in cystic fibrosis patients

✍ D. Hubert; S. Leroy; S. Dominique; J. Kovarik 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 64 KB

285 Pharmacokinetics of tobramycin nebul

285 Pharmacokinetics of tobramycin nebulizer solution (Bramitob®) administered by Pari e-Flow Rapid vs Pari LC Plus nebulizer in patients with cystic fibrosis and Pseudomonas aeruginosa infection

✍ M. Govoni; G. Poli; H. Cicirello; D. Santoro; D. Acerbi; J. Ruzicka 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 64 KB

Pharmacokinetic and tolerability profile

Pharmacokinetic and tolerability profiles of tobramycin nebuliser solution 300 mg/4 ml administered by PARI eFlow® rapid and PARI LC Plus® nebulisers in cystic fibrosis patients

✍ Govoni, Mirco; Poli, Gianluigi; Acerbi, Daniela; Santoro, Debora; Cicirello, Hel 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 290 KB

175 Dosing tobramycin in the inhalation

175 Dosing tobramycin in the inhalation therapy of Cystic Fibrosis — a comparison of LC PLUS used in breath triggered mode and EFLOW RAPID

✍ O. Pechtold; J. Stegemann; J. Paulukat; K. Sommerer 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 129 KB